inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by arterial oxygen saturation \< 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by arterial oxygen saturation \< 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: male or female subjects at least 18 years of age at time of consent. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. compromised respiratory status as defined by arterial oxygen saturation < 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. written informed consent provided by subject or legal representative.

inclusion criteria: male or female subjects at least 18 years of age at time of consent. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. compromised respiratory status as defined by arterial oxygen saturation < 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by arterial oxygen saturation < 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by arterial oxygen saturation < 92% (oxygen saturation measured by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by the following criteria to maintain arterial oxygen saturation ≥ 92% (where oxygen saturation is assessed by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review): 1. patients requiring noninvasive positive pressure ventilation. 2. patients on nasal canula with flow ≥ 4 l/minute or fraction of inspired oxygen (fio2) ≥ 36%). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by the following criteria to maintain arterial oxygen saturation ≥ 92% (where oxygen saturation is assessed by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review): 1. patients requiring noninvasive positive pressure ventilation. 2. patients on nasal canula with flow ≥ 4 l/minute or fraction of inspired oxygen (fio2) ≥ 36%). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by the following criteria to maintain arterial oxygen saturation ≥ 92% (where oxygen saturation is assessed by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review): 1. patients requiring mechanical invasive intubation. 2. patients requiring noninvasive positive pressure ventilation. 3. patients on non-rebreather face masks or high-flow nasal canula (flow ≥ 6 l/minute or fio2 ≥ 40%). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.

inclusion criteria: 1. male or female subjects at least 18 years of age at time of consent. 2. diagnosis of sars-cov-2 infection confirmed by real-time reverse transcription polymerase chain reaction (rt-pcr) assay. 3. compromised respiratory status as defined by the following criteria to maintain arterial oxygen saturation ≥ 92% (where oxygen saturation is assessed by pulse oximetry) or cardiomyopathy due to covid-19 (defined as a new drop in ejection fraction to ≤ 50% during covid-19 with no evidence of obstructive coronary artery disease based on medical records review): 1. patients requiring mechanical invasive intubation. 2. patients requiring noninvasive positive pressure ventilation. 3. patients on non-rebreather face masks or high-flow nasal canula (flow ≥ 6 l/minute or fio2 ≥ 40%). 4. elevation of at least 1 inflammatory marker (il-1, il-6, il-10, tnf-α, ferritin, crp) defined as ≥ 2x upper limit of laboratory normal reference value. 5. written informed consent provided by subject or legal representative.